Sanofi head of development Dietmar Berger
December 14, 2021 09:00 AM EST
R&D
Cell/Gene Tx

ASH: Sanofi un­corks late-stage da­ta for RNAi drug fi­tusir­an in he­mo­phil­ia, with all eyes on safe­ty pro­file

Kyle Blankenship

Sanofi’s fi­tusir­an has had a rough road in he­mo­phil­ia, weath­er­ing clin­i­cal holds and pro­gram halts tied to its lin­ger­ing safe­ty woes. Now, the drug is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times